Regulatory Information
APEX PHARMA MARKETING PTE. LTD.
APEX PHARMA MARKETING PTE. LTD.
Therapeutic
Prescription Only
Formulation Information
TABLET, FILM COATED
**Dosage** In the majority of cases, 2 tablets daily (1 tablet with breakfast, 1 tablet with dinner). Dosage can vary from 1–4 tablets daily, adjusted according to the individual patient's severity of Diabetes. The usual initial dose is 40 to 80mg daily. Doses of more than 160mg should be given in 2 divided doses. Maximum dose is 320mg daily.
ORAL
Medical Information
**Indication** **Melicron** is indicated for the treatment of non-insulin-dependent Diabetes Mellitus. It is used to supplement treatment by dietary modification when such modification has proved insufficient.
**Contraindications** **Melicron** should not be used alone in insulin-dependent diabetes; juvenile-onset diabetes; diabetes complicated by ketosis and acidosis; pregnancy; diabetics undergoing surgery, after severe trauma or during infections; precoma or coma; insulin should be given together and specific care needed. **Melicron** is contraindicated in patients hypersensitive to any other sulphonylureas and related drugs and patients with severe renal or hepatic insufficiency. When major surgery is to be performed, insulin therapy should be substituted for oral hypoglycaemia.
A10BB09
gliclazide
Manufacturer Information
APEX PHARMA MARKETING PTE. LTD.
XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD
Active Ingredients
Documents
Package Inserts
Melicron Tab PI.pdf
Approved: December 9, 2021